These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
562 related items for PubMed ID: 11007839
21. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids. Cantarovich D. J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885 [Abstract] [Full Text] [Related]
29. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group. Wiesel M, Carl S. J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430 [Abstract] [Full Text] [Related]
30. Observations on quadruple immunosuppression maintenance therapy using rapamycin, low-dose cyclosporine, mycophenolate mofetil, and prednisone following ATG induction. Khauli RB, Houjaij A, Sawah S, El-Hout Y, Medawwar W, Hussein M, Habbal A, Daouk M, Uwaydah M, Maacaron H, Abdelnoor A. Transplant Proc; 2005 Sep; 37(7):3031-3. PubMed ID: 16213295 [Abstract] [Full Text] [Related]
31. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation; 1996 Apr 15; 61(7):1029-37. PubMed ID: 8623181 [Abstract] [Full Text] [Related]
32. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Cantarovich M, Giannetti N, Barkun J, Cecere R. Transplantation; 2004 Sep 15; 78(5):779-81. PubMed ID: 15371689 [Abstract] [Full Text] [Related]
33. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S. Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352 [Abstract] [Full Text] [Related]
34. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Reddy KS, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Transplant Proc; 2010 Dec 20; 42(6):2006-8. PubMed ID: 20692393 [Abstract] [Full Text] [Related]
35. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Ekberg H, Persson NH, Källen R, Gül-Baykurt N. Scand J Immunol; 2003 Dec 20; 58(6):670-7. PubMed ID: 14636424 [Abstract] [Full Text] [Related]
36. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Kim YS, Moon JI, Kim SI, Park K. Transplantation; 1999 Aug 27; 68(4):578-81. PubMed ID: 10480420 [Abstract] [Full Text] [Related]
39. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. Zanker B, Schneeberger H, Rothenpieler U, Hillebrand G, Illner WD, Theodorakis I, Stangl M, Land W. Transplantation; 1998 Jul 15; 66(1):44-9. PubMed ID: 9679820 [Abstract] [Full Text] [Related]
40. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Abramowicz D, Del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P, Cyclosporine Withdrawal Study Group. J Am Soc Nephrol; 2005 Jul 15; 16(7):2234-40. PubMed ID: 15917338 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]